ABSTRACT ␣1-Adrenergic receptor (AR) subtypes in the heart are expressed by myocytes but not by fibroblasts, a feature that distinguishes ␣1-ARs from ␤-ARs. Here we studied myocyte-specific expression of ␣1-ARs, focusing on the subtype ␣1C (also called ␣1A), a subtype implicated in cardiac hypertrophic signaling in rat models. We first cloned the mouse ␣1C-AR gene, which consisted of two exons with an 18 kb intron, similar to the ␣1B-AR gene. The receptor coding sequence was Ͼ90% homologous to that of rat and human. ␣1C-AR transcription in mouse heart was initiated from a single Inr consensus sequence at Ϫ588 from the ATG; this and a putative polyadenylation sequence 8.5 kb 3Ј could account for the predominant 11 kb ␣1C mRNA in mouse heart. A 5Ј-nontranscribed fragment of 4.4 kb was active as a promoter in cardiac myocytes but not in fibroblasts. Promoter activity in myocytes required a single muscle CAT (MCAT) element, and this MCAT bound in vitro to recombinant and endogenous transcriptional enhancer factor-1. Thus, ␣1C-AR transcription in cardiac myocytes shares MCAT dependence with other cardiac-specific genes, including the ␣-and ␤-myosin heavy chains, skeletal ␣-actin, and brain natriuretic peptide. However, the mouse ␣1C gene was not transcribed in the neonatal heart and was not activated by ␣1-AR and other hypertrophic agonists in rat myocytes, and thus differed from other MCAT-dependent genes and the rat ␣1C gene.
nontranscribed fragment of 4.4 kb was active as a promoter in cardiac myocytes but not in fibroblasts. Promoter activity in myocytes required a single muscle CAT (MCAT) element, and this MCAT bound in vitro to recombinant and endogenous transcriptional enhancer factor-1. Thus, ␣1C-AR transcription in cardiac myocytes shares MCAT dependence with other cardiac-specific genes, including the ␣-and ␤-myosin heavy chains, skeletal ␣-actin, and brain natriuretic peptide. However, the mouse ␣1C gene was not transcribed in the neonatal heart and was not activated by ␣1-AR and other hypertrophic agonists in rat myocytes, and thus differed from other MCAT-dependent genes and the rat ␣1C gene.
␣1-Adrenergic receptors (␣1-ARs), one of three families of receptors for the endogenous catecholamines norepinephrine and epinephrine, are transcribed at different levels in different tissues. For example, ␣1-AR transcription is robust in rat heart muscle but low or nondetectable in skeletal muscle . Differential transcription is further evident within the rat heart, where ␣1-ARs are expressed only in cardiac myocytes, and not in cardiac parenchymal nonmyocytes or fibroblasts . In adult mouse heart also, ␣1-ARs are functional in myocytes but not fibroblasts (X. F. Deng, D. G. Rokosh, T. D. O'Connell, S. Cotecchia, and P. Simpson, in preparation) . The myocytespecific transcription of ␣1-ARs in heart contrasts distinctly with ␤-ARs, which are expressed by both cardiac myocytes and nonmyocytes (Lau et al., 1980) . Thus, catecholamine signaling in the myocardium activates ␣1-ARs only on myocytes, but ␤-ARs on both myocytes and nonmyocytes, which has important implications for catecholamine biology in the heart, and for cardiac hypertrophy and failure.
Suprisingly little is known about the mechanisms that control cell-specific transcription of ARs. Previous studies defined cell-specific promoters for the ␣1B, the ␣1C (also called the ␣1A-AR 2 ), and the ␣2C (Saulnier- Blache et al., 1996; Razik et al., 1997; Gao and Kunos, 1998; Zuscik et al., 1999) . However, only for the ␣1B in hepatocytes have further studies documented specific functional DNA sequence elements and their corresponding transcription factors (Gao and Kunos, 1998) .
Here we investigated mechanisms for transcription of the ␣1C-AR in cardiac myocytes. We focused on the ␣1C, rather than the other two subtypes, the ␣1B and ␣1D, because the ␣1C subtype mediates cardiac myocyte hypertrophy and hypertrophic gene induction in cultured rat myocytes (Knowlton et al., 1993; Autelitano and Woodcock, 1998) . Furthermore, the ␣1C is itself induced by ␣1-AR and other hypertrophic agonists in cultured rat myocytes and the intact rat (Rokosh et al., 1996; Autelitano and Woodcock, 1998) .
To study myocyte-specific expression of the ␣1C-AR, we first cloned and characterized the mouse gene and its transcription in mouse heart. We then defined a mouse ␣1C promoter in cultured neonatal rat cardiac myocytes, and examined the role of MCAT elements in activation of this promoter. MCAT DNA sequences share a consensus 5Ј-CATNC(C/T)(T/A) and bind members of the family of transcription factors called transcriptional enhancer factor-1 (TEF-1) (Larkin and Ordahl, 1998) . We focused on MCAT elements because they are required for transcription of several other cardiac myocyte genes in culture and in the intact heart (␣-and ␤-myosin heavy chain, skeletal ␣-actin, cardiac troponin T, and B-type natriuretic peptide) (Larkin and Ordahl, 1998) . In addition, MCATs are required for increased transcription during cardiac hypertrophy induced by ␣1C-AR and other hypertrophic agonists MacLellan et al., 1994; Karns et al., 1995; Gupta et al., 1997; Thuerauf and Glembotski, 1997; He and LaPointe, 1999) . However, no receptor gene in any tissue has so far been shown to require an MCAT for activity. Therefore, we tested the idea that MCATs might be a common transcriptional regulatory element shared by the ␣1C-AR and the other cardiac genes regulated by this receptor.
Materials and Methods
Cloning of the Mouse ␣1C-AR Gene. Initially, a FIX II 129SV mouse spleen genomic library (Stratagene, La Jolla, CA) was screened using rat ␣1C-AR cDNA probes to the first exon (PstI probe, Ϫ450 to 732 relative to ATG) or the second exon (SmaI probe from 1267 to 1827) . Restriction fragments from positive clones were subcloned into pBluescript (Stratagene) and sequenced using Thermo-sequenase PCR-based DNA sequencing (Amersham Pharmacia Biotech, Cleveland, OH).
Additional 5Ј-flanking sequence of the mouse ␣1C gene was obtained from a 129SV mouse bacterial artificial chromosome (BAC) library (Genome Systems, St. Louis, MO) using the first exon PstI probe. A positive BAC clone was isolated and digested with HindIII for a Southern blot using the PstI fragment as a probe; a positive fragment was isolated from an agarose gel, cloned into pBluescript, and sequenced.
Northern Blot. Total RNA was isolated from adult mouse heart, brain, and liver using guanidinium thiocyanate and extraction with phenol:chloroform:isoamyl alcohol. Thirty micrograms of total RNA from each tissue was separated on a 2.2% agarose/formaldehyde gel, transferred to a nylon membrane (Nytran plus; Schleicher & Schuell, Keene, NH), and cross-linked with UV irradiation. The blot was probed with an RNA probe to the first 494 bp of the first exon, and then reprobed with a 250 bp ␤-actin RNA probe. Template DNA for the ␣1C-AR probe was amplified from the BAC clone containing the first exon. RNA probes were transcribed (Maxiscript T7 kit; Ambion, Austin, TX) using [␣- 32 P]UTP 3000 Ci/mmol (PerkinElmer Life Science Products, Boston, MA) and then gel-purified. Blots were hybridized in Church buffer (0.1 M Na 2 HPO 4 pH 7.2, 1% bovine serum albumin, 1 mM EDTA, 7% SDS, and 35% formamide) for 20 h at 65°C, washed (twice with 0.1 M Na 2 HPO 4 /1% SDS for 15 min at 65°C, twice with 33 mM Na 2 HPO 4 /0.33% SDS for 15 min at 65°C, and finally twice with 3.3 mM Na 2 HPO 4 /0.03% SDS for 15 min at 65°C), and exposed to film (Biomax-MR; Eastman Kodak, Rochester, NY) at Ϫ70°C with an intensifying screen.
RNase Protection Assays (RPAs).
To locate the transcription initiation site of the ␣1C gene, total RNA from adult mouse heart was analyzed by RPA (RPA II kit; Ambion) using antisense RNA probes to the 5Ј-flanking sequence (probes 1 and 2: Ϫ650/ϩ1 and Ϫ801/Ϫ302, where ATG is ϩ1). Template DNA for the ␣1C-AR probes was amplified from the BAC clone containing the first exon. RNA probes were transcribed (Maxiscript T7 kit; Ambion) using [␣- 32 P]UTP 800 Ci/mmol (PerkinElmer Life Science Products) and then gel-purified. Purified probes (1 ϫ 10 6 cpm) were hybridized with 50 g of total RNA (or tRNA as a control) at 45°C overnight in 20 l of 80% deionized formamide, 100 mM sodium citrate pH 6.4, 300 mM sodium acetate pH 6.4, and 1 mM EDTA. Nonhybridized RNA was digested with RNase A (1 U/ml) and RNase T1 (40 U/ml). RNA duplexes were precipitated and separated on an 8 M urea/6% acrylamide gel. Gels were then exposed to film (Biomax-MR; Eastman Kodak) at Ϫ70°C with an intensifying screen.
To study ␣1-AR subtype mRNAs in neonatal and adult mouse heart, probes described previously were used in the same RPA protocol, except nonhybridized RNA was digested with only RNase T1.
Primer Extension Assays. A 20-bp antisense oligonucleotide primer was designed complimentary to the 5Ј-flanking sequence from Ϫ520 to Ϫ540 (relative to ATG) of the mouse ␣1C gene. The primer was end-labeled with [␥-32 P]ATP (PerkinElmer Life Science Products) using T4 polynucleotide kinase (Life Technologies, Gaithersburg, MD). Labeled primer was annealed for 10 min at 65°C to 2 g of mouse heart poly(A) RNA (purified from total RNA using the Poly(A) Pure kit; Ambion). Annealed RNA was then reverse transcribed with avian myeloblastosis virus reverse transcriptase for 30 min at 41°C according to the Primer Extension kit (Promega, Madison, WI), with the exception that the reverse transcriptase reaction was in the presence of 25 Ci of [␣-32 P]dCTP. The same 20 bp primer was used to sequence DNA from the mouse ␣1C-AR gene (Thermo-sequenase, Amersham). Primer extension and sequencing reactions were run on an 8 M urea/6% acrylamide gel, and gels were dried and exposed to film (Biomax-MR, Eastman Kodak) at Ϫ70°C with an intensifying screen.
Mouse ␣1C-AR Gene Promoter Constructs. Promoter constructs were cloned into a pUC9-CAT reporter plasmid , containing the multicloning site from pBluescript (KS). 5Ј-Flanking sequences were amplified from the HindIII BAC DNA clone by PCR using primers with unique restriction sites on each primer (SalI on the 5Ј primers and XbaI on the 3Ј primer). The 5Ј primers containing a SalI restriction site started at Ϫ4417, Ϫ3009, and Ϫ1307 bp relative to the transcription start site. A common 3Ј primer containing an XbaI restriction site started at ϩ14 relative to the transcription start site. Amplified products were digested sequentially with SalI and XbaI and cloned directionally into p0CAT. The resulting plasmids were named p4417-␣1CAR-CAT, p3009-␣1CAR-CAT, and p1307-␣1CAR-CAT. A 79-bp reporter construct was cloned in a similar manner. In this case, the 5Ј-flanking sequences were amplified from the HindIII BAC DNA clone by PCR using primers (5Ј primer Ϫ79 bp and 3Ј primer ϩ586 bp relative to the transcriptional start site) to amplify a blunt-ended product that was cloned into the SacI site in p0CAT.
Intronic sequences were cloned into the Ϫ46tkCAT plasmid that contains 46 bp of the thymidine kinase promoter (Karns et al., 1995) . Three constructs were made spanning a total of 5.7 kb of proximal intron sequence. Intronic DNA was digested with AvaI and SalI to release a 5.7 kb fragment, which was subsequently digested with HindIII to generate three fragments that were cloned into the Ϫ46tkCAT plasmid. The plasmids were 1.8AH-tkCAT, a 1.8-kb AvaI to HindIII fragment; 1.8H3-tkCAT, a 1.8-kb HindIII fragment; and 2.1HS-tkCAT, a 2.1-kb HindIII to SalI fragment.
Mutations to the p4417-␣1CAR-CAT Plasmid. Mutations to MCAT910 and MCAT1041 were made in the p4417-␣1CAR-CAT plasmid using a PCR-based mutagenesis protocol. Two primers around the site to be mutated, both 5Ј to 3Ј, with one primer complementary to each strand, incorporated the mutated base pairs. One primer of each pair was phosphorylated on the 5Ј end to facilitate ligation after amplification. The p4417-␣1CAR-CAT plasmid was used as the template. After amplification, the PCR products were treated with Klenow Fragment (Life Technologies) to create a blunt-ended product, digested with Dpn I (Roche Molecular Biochemicals, Indianapolis, IN) to remove the supercoiled template DNA, and ligated with T4 DNA Ligase (Roche Molecular Biochemicals) overnight at 16°C. DH5␣ competent cells (Life Technologies) were transformed with the ligation products. Mutations were confirmed using Thermo-sequenase PCR-based DNA sequencing (Amersham Pharmacia Biotech).
Cell Culture and Transfection. Neonatal cardiac myocytes were obtained from the hearts of day-old rats by serial trypsinization and cultured at low density in 60-mm dishes using defined medium as described previously (Long et al., 1991) . Myocytes were transfected in duplicate by the calcium phosphate precipitation method with 5 pmol (10-20 g) of one of the ␣1C-AR promoter constructs or p0CAT, 0.01 pmol (50 ng) of RSV-luciferase (RSV-LUX) as an internal control and differing amounts of pUC19 to adjust total DNA to 25 g/dish . In experiments with hypertrophic agonists, cells were treated with the following (from Sigma Chemical, St. Louis, MO, except as noted): norepinephrine bitartrate (RBI/Sigma, Natick, MA), timolol maleate, prazosin HCl, phenylephrine HCl, endothelin-1, phorbol-12-myristate-13-acetate (PMA), prostaglandin F-2␣ (R&D Systems, Minneapolis, MN), or vehicle (100 M ascorbic acid; Sigma Chemical, or 0.05% dimethyl sulfoxide for PMA and PGF2␣). CAT and luciferase activities were assayed 24 h later as described previously . In myocytes, luciferase activity was increased by cotransfection with the ␣1C-AR reporter plasmids (data not shown), and thus CAT activity was not normalized to luciferase in any experiment.
Cardiac fibroblasts were obtained from myocyte culture preplates as described previously (Long et al., 1991) , plated at 50,000 cells/60-mm dish, and transfected in duplicate by adenoviral-mediated transfection (Forsayethe and Garcia, 1994) , instead of calcium phosphate precipitation, because the nonmyocytes were more difficult to transfect than myocytes. Fibroblasts were transfected with 5 pmol of the ␣1C-AR promoter constructs and 0.2 pmol (1 g) RSV-LUX (internal control) by exposure to the adenovirus/DNA cocktail for 2 h, and then washed with and maintained in minimal essential medium with Hanks' salts with 5% calf serum. CAT and luciferase activities were determined as for myocytes. In fibroblasts, luciferase activity was not affected by cotransfection with the ␣1C-AR reporter plasmids (data not shown), but CAT activities were not normalized to luciferase.
Gel Mobility Shift Assays. Rat TEF-1⑀ for the binding reactions was produced in vitro using a reticulocyte lysate expression system (TnT Quick Coupled Transcription/Translation System; Promega). Nuclear extracts from cardiac myocytes were prepared as described previously (Kariya et al., 1993) . The radiolabeled probe for the gel shift assays was the 22-bp enhancer core/MCAT (EC/MCAT) sequence (Ϫ215/Ϫ194) from the rat ␤-myosin heavy chain promoter (Kariya et al., 1993 . Cold competitor probes from the ␣1C-AR promoter were designed encoding MCAT910, a mutant MCAT910, and MCAT1041 (Fig. 4A) . Binding reactions and analysis were as described previously (Kariya et al., 1993 , except that the gel contained 6% acrylamide, not 4%. Binding affinities for each competing oligonucleotide were compared by IC 50 values estimated from a logarithmic equation used to describe the competition curve.
Data Analysis. Results are given as mean Ϯ S.E.M. for the number of experiments indicated in each figure. Treated versus control values were tested for deviation from unity by calculation of confidence limits. Mean values were compared by the paired, twotailed Student's t test.
Results
Mouse ␣1C-AR Gene Cloning. We previously cloned the rat ␣1C-AR cDNA . To obtain the mouse ␣1C-AR gene, we screened a mouse spleen genomic library with rat ␣1C-AR cDNA probes to exons 1 and 2. We isolated two genomic clones (Fig. 1A, i and ii). The first (Fig. 1A, i ) contained 1.2 kb of 5Ј-flanking sequence, the entire 0.88 kb of coding sequence for the first exon of the mouse ␣1C-AR, and 11.9 kb of intron sequence. The second clone (Fig. 1A , ii) contained approximately 6 kb of intron sequence, the entire 0.52 kb of coding sequence for the second exon and 8.5 kb of 3Ј-flanking sequence. To obtain additional 5Ј-flanking sequence, we screened a mouse BAC library with the first exon PstI probe. We isolated a 7.7 kb HindIII fragment that contained 5 kb of 5Ј-flanking sequence, the entire 0.88 kb of coding sequence for the first exon and 1.8 kb of intron sequence (Fig. 1A, iii) . Analysis of the mouse ␣1C-AR primary sequence showed that the gene contained two exons separated by a large intron of at least 18 kb, inserted between the coding sequences for the sixth transmembrane domain and the third extracellular loop. This gene structure was identical to that of the ␣1B-AR (Ramarao et al., 1992; Gao and Kunos, 1993) .
Mouse ␣1C-AR Amino Acid Sequence. Figure 1B compares the mouse ␣1C-AR deduced amino acid sequence with the rat and human ␣1C-AR sequences. There was a 97% homology between the mouse and rat sequences and a 92% homology between the human and mouse. Most of the amino acids important for agonist binding or G protein coupling were conserved in the mouse ␣1C-AR (Fig. 1B legend) .
␣1C-AR Gene Transcription Initiation Site in Mouse Heart. We located the transcription initiation site of the ␣1C in adult mouse heart, using RPAs with probes from the cloned gene, followed by primer extension. As shown in Fig.  2A , RPAs were done using 50 g of total RNA from adult mouse heart and two different probes. Probe 1 (Ϫ650 to 1 relative to the ATG) gave a specific (absent in tRNA lane) 600-bp fragment ( Fig. 2A) . Based on these results, probe 2 was designed further upstream (Ϫ801 to Ϫ302 relative to the ATG) and gave a specific 275 bp fragment ( Fig. 2A) . Together, these results suggested the presence of a single major transcription initiation site, located between ϳ577 and ϳ600 bp upstream from the ATG.
To localize the transcription initiation site exactly, a 20 bp oligonucleotide complementary to the sequence from Ϫ520 to Ϫ540 (relative to the ATG) was used in primer extension assays with 2 g of poly(A) RNA from adult mouse heart. A single band was detected and aligned against 5Ј-flanking sequence of the mouse ␣1C (Fig. 2B) . This result defined a single transcription initiation site 588 bp upstream of the ATG. The mouse ␣1C promoter did not have a TATA box, but the initiation site contained an Inr initiator consensus sequence TCAGATA (6/7 match to consensus sequence Py Py A-1 N A/T Py Py) (Fig. 2B) (Lo and Smale, 1996) . The human ␣1C promoter is also TATA-less, and in a human neuroblastoma cell line has a major initiation site at an Inr consensus approximately 100 bp farther upstream of the ATG (at Ϫ696 bp) (Razik et al., 1997) . This difference in start site locations between the mouse and human ␣1C-AR genes might be due to different positions of the same Inr sequences. The human gene in neuroblastoma cells also has minor initiation sites closer to the ATG (Razik et al., 1997) .
␣1C-AR mRNA Transcription in Adult Mouse Heart. To compare ␣1C mRNA size and tissue distribution with that in the rat Stewart et al., 1994) , and to confirm the cloned gene structure, we did a Northern blot with 30 g of total RNA isolated from adult mouse heart, MCAT Dependence of the ␣1C-AR Promoter brain, and liver, using an RNA probe directed against the first 500 bp of exon 1 (Fig. 2C) . Mouse heart had a predominant ␣1C mRNA of 11 kb, with minor transcripts of 7.5 and 3.5 kb. Brain had similar mRNAs, and liver had none. Actin mRNA was detected in all tissues (Fig. 2C) . Thus, mouse ␣1C-AR mRNA size and tissue distribution were similar to that found in the rat Stewart et al., 1994) . Notable is the much larger size of ␣1C mRNA compared with ␣1B or ␣1D (ϳ2 kb) ( Fig. 2C ; Stewart et al., 1994) .
Sequencing identified four potential poly-adenylation sites in the 3Ј-flanking sequence of the mouse ␣1C gene, two ϳ2 kb 3Ј of the second exon and two more ϳ8 to 8.5 kb 3Ј (Fig. 1A) . Therefore, the size of the predominant 11 kb ␣1C-AR mRNA could be accounted for by ϳ600 bp of 5Ј-untranslated region, the 1.4 kb of coding sequence, and 8.5 kb of 3Ј-untranslated region before the final poly-adenylation signal (Fig. 1A) .
␣1C-AR mRNA Transcription in Mouse Heart Development. In the rat, all three ␣1-AR subtype mRNAs are expressed in the neonatal heart . To study expression during postnatal cardiac development in the mouse, we used RPA to detect the subtype mRNAs in mouse hearts of various ages (Fig. 2D) . As shown in Fig. 2D , the ␣1C was not detected in newborn (day 1) mouse heart of three different strains (C57BL/6, CD-1, and FVB), but was seen by weaning (day 21) in all strains. The ␣1B and ␣1D were present in the mouse heart at each time point (Fig. 2D) ; and all three subtypes were present in the newborn rat, confirming prior results . Thus, the ␣1C (Fig. 2,  below) , is indicated by an arrow, and four potential polyadenylation signals are marked 3Ј to the second exon. The three genomic clones used to characterize the gene are labeled i, ii, and iii. The PstI (Ϫ450 to 732 of exon 1) and SmaI (1267-1827 of exon 2) probes used in the cloning are shown beneath clones ii and iii. Enzyme abbreviations are given in the inset. B, alignment of ␣1C-AR deduced amino acid sequences from mouse, rat, and human. Dots indicate homology in all species. Nonconserved changes in amino acid sequence that could have structural significance are in boldface. Amino acids conserved with the ␣1B-AR and implicated in intracellular signaling are underlined, including residues important for agonist binding (C109 and S188/192) Perez et al., 1996) and G protein coupling (V209 to A243 and K268/A271) (Cotecchia et al., 1992; Wu et al., 1995; Perez et al., 1996) . N13 is a potential site for N-linked glycosylation, and is also conserved among ␣1 subtypes and across species in the ␣1C. The location of the intron is noted by double arrows. The seven transmembrane (TM) spanning regions and three intracellular loops are indicated. Asterisks are spaced every 10 amino acids. Rat sequences are from Stewart et al. (1994) , and human are from Schwinn et al. (1990). was not an early developmental mRNA in the mouse heart, in contrast with the rat.
Identification of a Mouse ␣1C-AR Promoter in Cardiac Myocytes and the Role of an MCAT Element in Promoter Activity. We showed previously that the ␣1C-AR is transcribed in rat cardiac myocytes, and not in cardiac nonmyocytes (fibroblasts) . ␣1-ARs are also functional in myocytes but not fibroblasts in the adult mouse heart (X. F. Deng, D. G. Rokosh, T. D. O'Connell, S. Cotecchia, and P. Simpson, in preparation). However, little is known about mechanisms that might regulate AR transcription in specific cells such as cardiac myocytes. Here we tested fragments of the cloned mouse ␣1C gene for promoter activity using transfection in cultured neonatal rat cardiac myocytes. We used rat myocytes rather than mouse as a test system, because the ␣1C was not transcribed in neonatal mouse myocytes (Fig. 2D) .
We focused on the possible role of MCAT elements in promoter activity, because MCATs are required for myocytespecific transcription of several structural genes and for in- Fig. 2 . Transcription of the ␣1C-AR in mouse heart. A, identification of the mouse ␣1C-AR transcriptional initiation site in heart by RPA. Antisense RNA probes from Ϫ650 to ϩ1 and Ϫ801 to Ϫ302 (ATG ϩ1) of the 5Ј-flanking sequence of the mouse ␣1C-AR (shown on left) were labeled with [␣-32 P]dUTP and used in a RPA with 50 g of total RNA from adult mouse heart or 50 g of control tRNA. The gel lanes show the probe alone (Pr), tRNA control (tR), and heart RNA (H). Protected fragments in the heart RNA lane are labeled by approximate size, 600 bp with probe 1 and 275 bp with probe 2. These results indicate a single major transcriptional start site located approximately 577 to 600 bp upstream of the ATG. B, identification of the mouse ␣1C-AR transcriptional initiation site in heart by primer extension. Primer extension was used to localize the transcription initiation site precisely. Poly(A) RNA (2 g) from mouse heart was used in a primer extension assay with a 20 bp antisense oligonucleotide primer against the sequence from Ϫ520 to Ϫ540 (ATG ϩ1). The same primer was used to sequence DNA from the 5Ј-flanking sequence of the mouse ␣1C gene. The sequence is shown in the figure aligned with the primer extension reaction. The transcription initiation site is 588 bp upstream of the ATG and encompasses an Inr sequence TCAG(Ϫ588)ATA (sequence shown on the left). C, identification of mouse ␣1C-AR by Northern blot. Total RNA (30 g) from adult mouse heart (H), brain (B), and liver (L) was probed with an [␣-32 P]dUTP-labeled antisense RNA probe encompassing nucleotides 3 to 497 of the first exon of the ␣1C-AR gene (top). The same blot was stripped and reprobed with a 250 bp ␤-actin probe (bottom); sarcomeric (seen only in heart) and cytoskeletal actin are labeled. The molecular weights of the ␣1C-AR mRNAs are shown on the left. Molecular weight size markers and ribosomal RNA mobility are shown on the right. D, ␣1-AR subtype mRNAs in mouse heart development by RPA. Antisense RNA probes to the rat ␣1-AR subtypes ␣1B, ␣1C, and ␣1D (Rokosh et al., 1994) , and to ␤-actin, were labeled with [␣-32 P]dUTP and used in RPA with 25 g of total RNA from a newborn rat heart (day 1), newborn mouse heart (day 1; one litter pooled), and weanling mouse heart (day 21). RNA was made from hearts of three different mouse strains: C57BL/6J (BL/6), CD-1, and FVB/NJ (FVB). The ␣1C was not detected in the newborn heart in any mouse strain.
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As diagrammed in Fig. 3A , 4.4 kb of sequence 5Ј to the transcription start site contained numerous consensus elements, including seven MCATs, nine GATA elements, two a cAMP response elements (CREs), and single SP1 and AP-1 sites. As shown in Fig. 3B , a CAT reporter plasmid containing this 4.4 kb sequence was active as a promoter in cardiac myocytes. The level of activity (2.3 Ϯ 0.2-fold versus empty reporter vector, n ϭ 20, p Ͻ 0.05) was consistent with the lower relative level of endogenous ␣1C transcription, as compared with ␤-myosin heavy chain and skeletal ␣-actin, two other promoters we have studied in this identical system Karns et al., 1995) .
To test whether sequences in addition to the 4.4 kb were active in myocytes, we also studied 5.8 kb of proximal intron sequence. We made heterologous reporter plasmids in thymidine kinase (tk)-CAT containing sequential intron fragments (from the end of the first exon) of 1.8, 1.8, and 2.1 kb. None of these intron reporter plasmids had detectable activity in myocytes (0.9 Ϯ 0.1-, 0.8 Ϯ 0.0-, and 0.9 Ϯ 0.1-fold versus empty vector, n ϭ 2).
To further define the DNA elements required for activity of the 4.4 kb fragment in myocytes, deletion mutants were constructed that contained only ϳ3 or ϳ1.3 kb of 5Ј sequence, and identical 3Ј ends (Fig. 3A) . Full promoter activity was retained in a 1.3 kb reporter (2.2 Ϯ 0.2-fold, n ϭ 10, p Ͻ 0.05, Fig. 3B ), whereas activity was lost in a 79-bp reporter (data not shown).
As a control, we also tested these ␣1C reporter plasmids in cultured rat nonmyocytes or fibroblasts, where the endogenous ␣1C is not transcribed. As shown in Fig. 3B , none of the reporter plasmids had detectable activity in nonmyocytes. However, the control RSV-luciferase reporter was expressed in nonmyocytes (data not shown), demonstrating that these cells were transfected. Thus, these results defined a mouse ␣1C promoter that mimicked the myocyte-specific expression of the endogenous ␣1C in heart cells .
Among the seven consensus MCAT elements present in the 4.4 kb promoter (Fig. 3A) , only two remained in the 1.3 kb minimal promoter, MCATs named M1 and M2 (Fig. 3B) . To test whether either or both of these MCATs was required for activity, we introduced point mutations into each MCAT. We made the MCAT mutations in the context of the full-length 4.4 kb reporter plasmid, where all other potential regulatory elements were intact (Fig. 3A) . As shown in Fig. 3C , mutation of MCAT M1 (at Ϫ910 from the transcription start site) reduced CAT activity of the 4.4 kb construct to levels of the empty vector (1.0 Ϯ 0.1-fold versus empty vector, n ϭ 5). Mutation of MCAT M2 (at Ϫ1041) had no effect (2.2 Ϯ 0.1-fold, n ϭ 3), and double mutation of both MCATs was the same as mutation of MCAT M1 alone (1.1 Ϯ 0.1-fold, n ϭ 5) (Fig. 3C) . Thus, these results indicated that ␣1C-AR promoter activity in cardiac myocytes required MCAT M1 at Ϫ910. Importantly, the active MCAT M1 at Ϫ910 is conserved in the human ␣1C-AR promoter, whereas the inactive MCAT M2 at Ϫ1041 is not, although MCAT functionality in the human promoter was not tested (Razik et al., 1997) .
TEF-1 Binds the Active ␣1C Promoter MCAT Element M1. MCAT elements bind members of the family of transcription factors known as TEF-1 (Larkin and Ordahl, 1998) , and TEF-1-binding MCATs are required for transcription of several contractile protein genes and cardiac BNP (see Introduction). We have studied in detail an MCAT in a 22-bp sequence (Ϫ215 to Ϫ194) in the rat ␤-myosin heavy chain promoter, named the proximal EC/MCAT. The EC/MCAT is required for promoter activity in myocytes and binds to TEF-1 in vitro and in vivo (Kariya et al., 1993 Stewart et al., 1998) . To test whether the M1 MCAT required for ␣1C promoter activity also bound to TEF-1, we did competition gel mobility shift assays, using the EC/MCAT as the probe and both recombinant TEF-1 and endogenous TEF-1.
With recombinant TEF-1, the EC/MCAT probe formed one major complex (Fig. 4A, lane 2 ) that was competed with increasing concentrations of unlabeled EC/MCAT probe (lanes 3-5). The MCAT M1 oligonucleotide (MCAT910) also competed for TEF-1 binding (lanes 6-8), whereas a mutated version of this oligonucleotide (MCAT910 mut) did not compete (lanes 9-11), indicating that TEF-1 bound to MCAT M1. Interestingly, the MCAT M2 oligonucleotide (MCAT1041) also competed for TEF-1 binding (lanes 12-14), and more efficiently than did the EC/MCAT or the MCAT M1 oligonucleotides (lanes 12-14 versus 3-5 and 6-8).
Replicate experiments are summarized in Fig. 4B , which quantifies binding affinity and shows the approximate IC 50 for each competing oligonucleotide. The graph shows that TEF-1 binds with lower affinity to the two active MCATs (157 nM for MCAT M1 at Ϫ910 and 24 nM for the EC/MCAT) than to an inactive MCAT (4 nM for MCAT M2 at Ϫ1041).
To test whether endogenous TEF-1 bound to these oligonucleotides the same as recombinant TEF-1, the gel shift assay was done with cardiac myocyte nuclear extracts (Fig.  4C ). Myocyte nuclear extracts and the EC/MCAT probe produced a shifted duplex band named C2 (Fig. 4C, lanes 2, 4, 6 , and 8). Earlier we showed conclusively by immunoblot of a gel shift that this band contains TEF-1 (Kariya et al., 1993 . In further agreement with prior results, this complex was competed by unlabeled probe, showing specificity (Fig.  4C, lane 3) . The MCAT M1 oligonucleotide (MCAT910) competed for endogenous TEF-1 binding (lane 5), whereas a mutated version of this oligonucleotide (MCAT910 mut) did not compete (lane 7). The MCAT M2 oligonucleotide (MCAT1041) also competed for endogenous TEF-1 binding (lane 9). The relative order of TEF-1 affinity for the oligonucleotides was the same for endogenous TEF-1 in these nuclear extracts: MCAT1041 Ͼ EC/MCAT Ͼ MCAT910 (lanes 9 Ͼ 3 Ͼ 5), as for recombinant TEF-1 (Fig. 4, A and B) .
Activation of the Mouse ␣1C-AR Promoter by Norepinephrine and Other Hypertrophic Agonists. In the rat, hypertrophic stimuli increase ␣1C-AR mRNA in cardiac myocytes in culture and in vivo (Rokosh et al., 1996) . To test whether hypertrophic agonists stimulated the mouse ␣1C-AR promoter, rat myocytes were transfected with the full-length 4.4 kb ␣1C promoter, and then treated with various agonists for 24 h. Norepinephrine increased ␣1C promoter activity by ϳ4-fold versus vehicle. However, the norepinephrine effect was mediated entirely through a ␤-AR, because induction was blocked by the ␤-AR antagonist timolol and not by the ␣1-AR antagonist prazosin (Fig. 5) . Phenylephrine mildly activated the promoter, but this was blocked by timolol, consistent with a slight ␤-AR action of 20 M phenylephrine (Fig. 5 ). Endothelin and PGF2␣ had no effect, and PMA induced the promoter only slightly, albeit significantly (Fig. 5) . Fig. 3 . Analysis of an ␣1C-AR promoter in rat heart cells. A, mouse ␣1C-AR promoter and reporter constructs. The top of the figure shows the locations of potential cis-regulatory elements (relative to the transcription initiation site), including seven consensus MCAT motifs. An asterisk indicates elements conserved with the human sequence (Razik et al., 1997) . The bottom of the figure diagrams the three CAT reporter plasmids, containing ϳ4.4, 3.0, and 1.3 kb of sequence. B, activity of the mouse ␣1C-AR promoter in cardiac myocytes and nonmyocytes. The three CAT reporter plasmids containing 4417, 3009, and 1307 bp of promoter sequence were transiently transfected into primary cultures of rat neonatal cardiac myocytes and nonmyocytes. Cardiac myocytes were cultured in serum-free medium, whereas nonmyocytes were cultured in serum-supplemented medium to maximize any expression of the reporters. These were exactly the same conditions where myocytes but not fibroblasts have ␣1-AR mRNAs, proteins, and function (Rokosh et al., 1996, and references therein) . CAT activity was measured after 24 h. The graph shows the constructs on the left and the corresponding CAT activity on the right, expressed as fold activation relative to p0CAT (empty vector). The locations of the seven MCAT elements (M1-M7) are indicated. An RSV-luciferase construct was cotransfected as a control, but CAT activities were not corrected for luciferase expression. Each experiment was performed with duplicate dishes, and data are presented as mean Ϯ S.E.M. (n ϭ 10 -20 experiments in myocytes, n ϭ 3 experiments in nonmyocytes). *p Ͻ 0.05 versus p0CAT. C, activity of mouse ␣1C-AR promoter MCAT mutants in cardiac myocytes. Point mutations were made in MCATs M1, M2, or both (double, dbl) in the context of the full-length 4.4 kb ␣1C promoter (M1 CATGCCA mutated to CgatCgA, M2 CATACTT to CgatCgT, mutations in lowercase; see also 
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The ␤-AR activation of the promoter was mediated partly by a CRE 156 bp upstream of the transcriptional start site (CRE156, CCTACGTCAGGGC, site underlined). Mutation of the CRE (CCTACcctAGGGC, mutations in lowercase) had little effect on basal activity (data not shown), but reduced norepinephrine induction by half (2.3 Ϯ 0.2-fold versus vehicle, n ϭ 3). Mutation of MCAT M1 at Ϫ910, or of both MCAT M1 and MCAT M2 at Ϫ1041, reduced basal activities to levels of the empty vector (Fig. 3C ), but did not impair norepinephrine induction (MCAT M1 5.1 Ϯ 0.4-fold, n ϭ 3; MCAT M1 and M2 4.2 Ϯ 0.7, n ϭ 3).
Interestingly, a phenylephrine ("␣1-AR") response element (GGGGAGGG) as defined in the atrial natriuretic factor promoter (Ardati and Nemer, 1993 ) is found in the human ␣1C promoter (Razik et al., 1997) and was also present in the mouse promoter (PERE at Ϫ3102, Fig. 3A) . However, the data in Fig. 5 indicated that this PERE was not sufficient for ␣1-AR activation. Indeed, there was no major activation by ␣1-adrenergic or other Gq-coupled agonists, and there was no MCAT-dependent stimulation of the mouse ␣1C promoter.
Discussion
Here we cloned and characterized the complete structure of the ␣1C-AR gene and characterized transcription of the gene in adult mouse heart. We defined an ␣1C promoter that was active in cultured neonatal rat cardiac myocytes but not fibroblasts and showed that activity of the promoter required an MCAT element that bound TEF-1. This is the first example of a receptor gene regulated by an MCAT element, and one of the few cases (Gao and Kunos, 1998) to identify a mechanism for adrenergic receptor transcription in a specific cell.
The structure of the ␣1C-AR gene was similar to that of the ␣1B-AR (Ramarao et al., 1992; Gao and Kunos, 1993) , in that the gene contained two exons separated by a large intron (at least 18 kb). Similar to the major promoter of the ␣1B (Gao and Kunos, 1993) , the ␣1C promoter was TATA-less, and transcription in mouse heart was initiated from a single site that contained an Inr consensus. This Inr is possibly the same one used by the human ␣1C promoter for transcription initiation in neural cells (Razik et al., 1997) . The predominant ␣1C mRNA in both mouse and rat heart, ϳ11 kb, is much larger than the mRNAs of the ␣1B or ␣1D in heart (both ϳ2 kb) ( Fig. 2C ; Stewart et al., 1994) . Here we were able to account for this long ␣1C mRNA by transcription from the Inr at Ϫ588 upstream of the ATG, 1.4 kb of open reading frame, and a potential polyadenylation sequence 8.5 kb downstream.
We identified a 4.4 kb fragment of mouse ␣1C-AR 5Ј-nontranscribed sequence that was active as a promoter in cultured neonatal rat myocytes but not in nonmyocytes, and thus mimicked the myocyte-specific transcription of the endogenous ␣1C gene in the heart. The magnitude of ␣1C promoter activity, ϳ2.5-fold over empty vector, was congruent with the much lower abundance of endogenous ␣1C transcripts in comparison with the structural genes ␤-myosin heavy chain and skeletal ␣-actin (Bishopric et al., 1987;  with the indicated concentration of cold oligonucleotides. The molar concentration of oligonucleotide giving 50% inhibition of binding to the EC/MCAT (IC 50 ) was estimated from the competition curves as ϳ4 nM for MCAT M2 (MCAT1041), ϳ24 nM for the EC/MCAT, and ϳ157 nM for MCAT M1 (MCAT910). The mutated version of MCAT M1 (MCAT910 mut) did not compete 50% of TEF binding even at 100ϫ. Points are mean Ϯ range, n ϭ 2. C, endogenous TEF-1 in cardiac myocyte nuclear extracts binds to the ␣1C MCAT elements. Gel shift was done as in A, using 10 g of cardiac myocyte nuclear extract. The TEF-1 shifted complex (C2) is indicated on the left (see also Kariya et al., 1993) , and the unlabeled competitors (100-fold) are indicated at the top of each lane. (Kariya et al., 1993 was labeled with [␥- 32 P]dATP and incubated with in vitro translated TEF-1⑀, in the presence or absence of increasing amounts of unlabeled competitor oligonucleotides. Sequences of the proximal enhancer core/MCAT probe and the competitor oligonucleotides are shown at the top of the figure. Bound and free probe were separated on a 6% gel and visualized on film by autoradiography. The shifted TEF-1 band is indicated by the arrow on the left, and the fold concentrations of each competitor are indicated at the top of each lane. B, TEF-1 binding affinity for MCAT elements. Densitometry was used to quantify the gel shift bands in A and in an additional identical experiment. The graph shows the percentage of labeled probe bound to TEF-1 after competition Waspe et al., 1990; Stewart et al., 1994; Rokosh et al., 1996) ; these latter promoters are activated ϳ10-fold over basal in the same system Karns et al., 1995) .
A single MCAT element, MCAT M1 at Ϫ910 from the Inr, was required for activity of the full-length promoter in myocytes and bound recombinant and endogenous TEF-1 in gel mobility shift assay. Thus, an MCAT element that bound TEF-1 was required for ␣1C transcription in myocytes. This active MCAT in the ␣1C-AR promoter is conserved in the human gene, although its activity was not tested (Razik et al., 1997) , just as an active MCAT in the rat ␤-myosin heavy chain promoter is conserved among species . It is intriguing that an identical MCAT/TEF-1 mechanism is used in myocytes for transcription of the ␣1C receptor gene and for transcription of several other cardiac genes (␣-and ␤-myosin heavy chain, skeletal ␣-actin, cardiac troponin T, and B-type natriuretic peptide) (see Introduction). This observation links an MCAT/TEF-1 signaling mechanism that maintains the cardiac myocyte phenotype to ␣1C transcription in myocytes, and suggests a possible autoregulatory system for transcription. That is, MCATs and TEF-1 promote transcription of genes that are targets for ␣1C signaling, such as contractile proteins and cardiac BNP MacLellan et al., 1994; Karns et al., 1995; Gupta et al., 1997; Thuerauf and Glembotski, 1997; He and LaPointe, 1999) , and also transcription of the receptor gene itself. The ␣1B promoter similarly contains at least one MCAT (Saulnier-Blache et al., 1996; Razik et al., 1997; Gao and Kunos, 1998; Zuscik et al., 1999) , although it is not known whether the ␣1B MCAT is functional. We are further exploring a possible connection in myocytes between the ␣1C receptor and TEF-1 using mice with gene knockouts (O'Connell et al., 2000a,b) and studies of ␣1C signaling. Consistent with a connection we find that TEF-1 phosphorylation is altered by ␣1C-AR stimulation (R. Q. To, C. Turck, and P. Simpson, unpublished observations).
It was initially surprising in this regard that the mouse ␣1C promoter was not activated by ␣1-AR or other Gq-coupled hypertrophic agonists (Fig. 5) , whereas the rat ␣1C gene is activated robustly by hypertrophic stimuli in culture and in the intact rat (Rokosh et al., 1996; Autelitano and Woodcock, 1998) . However, recent data confirm that the endogenous mouse ␣1C gene also differs from the rat. In the mouse, ␣1C mRNA in myocytes does not increase with hypertrophy in vivo (Snyder et al., 1999; Wang et al., 2000) , in contrast with the rat where it does increase (Rokosh et al., 1996) . For example, abdominal aortic banding, which increases ␣1C mRNA in rat heart (Rokosh et al., 1996) , does not do so in the mouse (Snyder et al., 1999 ; D. G. Rokosh, P. C. Simpson, unpublished observations).
At least two mechanisms could account for the difference in ␣1C transcription with hypertrophic stimuli between rat and mouse: differences in intracellular signaling and/or differences in gene structure. Our results favor differences in gene structure, because we tested the mouse gene in rat myocytes, where signaling does activate the endogenous ␣1C. For example, the rat ␣1C gene might contain an "inducible" MCAT, or some other hypertrophic response element, not present in the mouse gene. In this regard it is interesting that inducible MCATs have an A or a T at the fourth position, rather than the G found in the "noninducible" MCAT M1 at Ϫ910 in the mouse ␣1C-AR promoter (Fig. 4A) . A structural gene difference might also explain why ␤-AR stimulation activates the mouse promoter (Fig. 5) but not the rat (Rokosh et al., 1996) . ␤-AR activation of the mouse ␣1C promoter required a CRE, rather than an MCAT/E-box as in the ␣-myosin heavy chain promoter (Gupta et al., 1994) , and the rat gene might lack the required CRE found in the mouse. The mechanism(s) require further study, but the results do indicate important differences in transcription activation between the rat and the mouse, comparable with those seen previously with atrial natriuretic factor (Seidman et al., 1991) .
Another transcription difference between rat and mouse is more probably explained by differences in signaling rather than gene structure, the delayed maturation of ␣1C transcription during development in the mouse. In the newborn heart, the ␣1C is not transcribed in the mouse, but is transcribed in the rat (Fig. 2D) . Because we studied the mouse promoter in neonatal rat myocytes, we know that the structure of the mouse gene supports transcription in neonatal cells. Thus absent transcription in neonatal mouse myocytes might reflect some rat-mouse difference(s) in signaling, such as a kinase that activates TEF-1, a TEF-1-interacting protein (see below), or a mechanism that unfolds chromatin over the active mouse MCAT element.
Finally, it was noteworthy that only one of the seven MCAT consensus elements in the mouse ␣1C promoter was required for activity in myocytes, emphasizing the need for functional studies such as those reported here. Similar observations in other promoters Larkin and Ordahl, 1998) have raised the idea that TEF-1 requires 5 . Activation of the mouse ␣1C-AR promoter and promoter mutants by norepinephrine and other hypertrophic agonists. Cardiac myocytes on culture day 1 were transfected for 2 h with p4417-␣1CAR-CAT, and then treated the next day with various hypertrophic agonists. CAT activity was measured after 24 h, and is shown here relative to the vehicle-treated control cells. An RSV-luciferase construct was cotransfected as a control, but CAT activities were not corrected for luciferase expression. Each experiment was performed with duplicate dishes, and data are presented as mean Ϯ S.E.M. *p Ͻ 0.05 versus vehicle. Abbreviations of agonists and numbers of experiments (in parentheses) are as follows: doses were 2 M except as noted: VEH, vehicle (20); NE, norepinephrine (16); NE/PZN, NE plus prazosin 0.2 M (3); NE/TML, NE plus timolol (5); PE, phenylephrine 20 M (4); PE/TML, PE plus timolol (4); ET-1, endothelin-1 100 nM (3); PMA 100 nM (3); PGF2␣ 1 M (3).
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at ASPET Journals on March 31, 2017 molpharm.aspetjournals.org some additional cofactor for activity in myocytes. Indeed "active" MCATs in myocytes can have apparently lower binding affinity for TEF-1 than inactive MCATs (Kariya et al., 1993 ; I. K. G. Farrance and P. C. Simpson, unpublished observations), as we observed in this study with both recombinant and endogenous TEF-1 (Fig. 4) . Lower affinity TEF-1 binding at an active MCAT might favor a protein conformation that allows for association with a required coactivator. A few TEF-1 coactivators are known, including Max in the ␣-myosin heavy chain promoter (Gupta et al., 1997) and poly(ADP-ribose) polymerase in the cardiac troponin T promoter (Butler and Ordahl, 1999) . However, the active MCAT M1 at Ϫ910 is not flanked by an E-Box (CANNTG; Max binding site) as in the ␣-myosin heavy chain promoter (Gupta et al., 1997) , or a poly(ADP-ribose) polymerase binding site (TGTTG) as in the cardiac troponin T promoter (Butler and Ordahl, 1999) . In addition, MCAT element M7 (Fig. 3A) is flanked by a poly(ADP-ribose) polymerase-binding site, but was not required for ␣1C-AR promoter activity. Thus, it is likely that novel TEF-1-interacting proteins exist, such as the human protein TONDU, related to vestigal in Drosophila (Vaudin et al., 1999) , and several labs are pursuing this idea.
